ASH 2019 | Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results

[Manouche]

vjhemonc.com/video/elvsbiyx...

[saturn0325]

Besremi will obtain the Taiwan PV drug certificate as soon as April 2020, and Taiwan will also become the first beneficiary country for PV patients in Asia.

[Bluetop]

Thanks for posting Manouche. It all seems so poitive, but when these results were presented at the Patient Forum in London, all the panel (except Prof. Kiladjian from France who presented the figures and had to leave early ) said that despite these results, they would not recommend that a PV patient who was doing well on Hydroxy should be switched to Ropeg. Unfortunately there wasn't time to discuss this further and to answer the question, 'why not?' But certainly a question for my haem.

[Manouche in reply to Bluetop]

The hematologist’s attitude is weird sometimes, but they are like all human beings I suppose, they are scared to change their habit and/or their belief.

[hunter5582 in reply to Manouche]

I suspect multiple reasons - fear of change from what docs are used to is one of them. "Better the devil I know" sort of thinking. sadly, the drive from healthcare systems to save money on cheaper drugs is also an issue. As someone who is HU-intolerant, I am really glad to see solid evidence of potentially better alternatives. FY - the MPN Specialist I consulted with does not recommend HU for anyone. He feels the benefit-risk profile for INF is better for the patient.

[Aneliv9]

It doesn't have sound . Can you make a quick abstract?

[Manouche in reply to Aneliv9]

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

eventpilot.us/web/page.php?...

[Aneliv9 in reply to Manouche]

Thank you very much. Indeed very promising